VistaGen Therapeutics is a
California-based biotechnology company that specializes in the application of
human pluripotent stem cell (hPSC) technology for drug rescue, including
predictive toxicology and drug metabolism screening. The company’s hPSC
technology platform, Human Clinical Trials in a Test Tube™, enables
accessibility to the heart and liver safety profile of drug rescue variants and
other new drug candidates with greater speed and precision than conventional
nonclinical testing and technologies used in drug development. Harnessing this
technology’s unique power, VistaGen Therapeutics enables “drug rescue” of
once-promising-but-now-backshelved drug candidates that have been discontinued
by biotechnology or pharmaceutical companies prior to market approval due to
unexpected heart or liver safety concerns.
Recently, the company made
an appearance at Noble Financial Capital Markets’ 9th Annual Equity Conference.
The conference took place Wednesday, January 22, 2014 to Thursday, January 23,
2014 at the Seminole Hard Rock Hotel in Hollywood, Florida. There, some 100
publicly held companies’ corporate representatives showcased their companies’
profiles, business strategies, and outlooks. Investment portfolio managers and
equity analysts were on hand to analyze the representatives’ presentations, ask
questions, and get a good all-around sense of how each business offers growth
potential.
At the event, Mr. Shawn K.
Singh, J.D., Chief Executive Officer of VistaGen Therapeutics, said that
VistaGen Therapeutics is “changing the game” in the area of stem cell
technology. Noting his experience of 22 years in the biotech space, Mr. Singh
noted that 2014 will be the “breakout year” for the company.
Having touched upon his
executive experience, he then said that the company is “applying stem cell
technology in ways [he] has not seen possible in the last couple of decades in
this space.” According to a Forbes article from February 2012, the sunk cost of
drug development is huge, as the “average drug developed by a major
pharmaceutical company costs at least $4 billion.” Likewise, the failure of
drug development was noted to be staggering and largely attributable to heart
or liver toxicity, with over 50% of drug development efforts failing due to
these medical concerns.
Mr. Singh touched upon the
efficacy of Human Clinical Trials in a Test Tube in combating these sunk cost
risks, as the hPSC technology platform identifies failure potential early in a
drug’s development process before too many cost have been paid. In short, the
technology lets pharmaceutical companies “bring human biology to the forefront
of drug development”, thereby letting them “change the game early” in their
drug development stages. He then went on to discuss other key company focuses
and goals for 2014.
The entirety of Mr. Singh’s
presentation at the Noble conference can be found at:
http://noble.mediasite.com/mediasite/Play/7b2df397209e4accad8b01e55857bb431d?catalog=7196f4ed-1981-4e62-afb2-e3a1f13bc7fb
For more information about
VistaGen Therapeutics and its technologies, visit: http://www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
